Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1967 1
1972 1
1975 4
1976 3
1977 3
1978 1
1979 3
1980 4
1981 1
1982 3
1983 1
1984 4
1985 4
1986 1
1987 2
1988 2
1989 5
1990 3
1991 3
1992 5
1993 2
1994 2
1995 3
1996 5
1997 3
1998 3
1999 4
2000 9
2001 7
2002 11
2003 17
2004 8
2005 7
2006 6
2007 3
2008 7
2009 10
2010 12
2011 13
2012 10
2013 15
2014 18
2015 9
2016 5
2017 11
2018 11
2019 7
2020 15
2021 23
2022 25
2023 14
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

316 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Macroglobulinemia, Waldenstrom, 2"
Page 1
Waldenstrom macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA. Gertz MA. Am J Hematol. 2023 Feb;98(2):348-358. doi: 10.1002/ajh.26796. Epub 2023 Jan 1. Am J Hematol. 2023. PMID: 36588395 Free PMC article.
DISEASE OVERVIEW: Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. ...RISK STRATIFICATION: Age, hemoglobin level, platelet count, beta(2) microglobulin, LDH, and monoclonal IgM concentrations a …
DISEASE OVERVIEW: Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal pr …
Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA. Gertz MA. Am J Hematol. 2021 Feb 1;96(2):258-269. doi: 10.1002/ajh.26082. Am J Hematol. 2021. PMID: 33368476 Free article. Review.
DISEASE OVERVIEW: Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. ...RISK STRATIFICATION: Age, hemoglobin level, platelet count, beta(2) microglobulin, LDH and monoclonal IgM concentrations ar …
DISEASE OVERVIEW: Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal pr …
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Röth A, et al. Blood. 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. Blood. 2022. PMID: 35687757 Free PMC article. Clinical Trial.
Composite primary endpoint criteria (hemoglobin increase 1.5 g/dL at treatment assessment timepoint [mean of weeks 23, 25, 26], avoidance of transfusion, and study-prohibited CAD therapy [weeks 5-26]) were met by 16 patients (73%) on sutimlimab, and 3 patients (15%) on placebo (o …
Composite primary endpoint criteria (hemoglobin increase 1.5 g/dL at treatment assessment timepoint [mean of weeks 23, 25, 26], avoidance of …
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. Davids MS, et al. J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17. J Clin Oncol. 2017. PMID: 28095146 Free PMC article.
Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. ...Results NHL subtypes included mantle cell lymphoma (MCL; n = 28), follicular lymphoma (FL; n = 29), diffuse large B-cell lymphoma (DLBCL; n = 34), DLB …
Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. ...Results NH …
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Buske C, et al. J Clin Oncol. 2022 Jan 1;40(1):52-62. doi: 10.1200/JCO.21.00838. Epub 2021 Oct 4. J Clin Oncol. 2022. PMID: 34606378 Free PMC article. Clinical Trial.
PURPOSE: The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenstrom's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. ...PFS benefit was regardless of prior tre …
PURPOSE: The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Wa …
CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies.
Le Cann M, Bouhour F, Viala K, Simon L, Tard C, Rossi C, Morel G, Lagrange E, Magy L, Créange A, Michaud M, Franques J, Echaniz-Laguna A, Antoine JC, Baron M, Arnulf B, Puma A, Delmont E, Maisonobe T, Leblond V, Roos-Weil D. Le Cann M, et al. Blood. 2020 Nov 19;136(21):2428-2436. doi: 10.1182/blood.2020007092. Blood. 2020. PMID: 32959046 Free article.
Forty-five percent of the cohort had moderate to severe disability (modified Rankin score, 3-5). Cold agglutinins were identified in 15 (34%) patients. Electrophysiologic studies showed a demyelinating or axonal pattern in, respectively, 60% and 27% of cases. All patients …
Forty-five percent of the cohort had moderate to severe disability (modified Rankin score, 3-5). Cold agglutinins were identified in …
Report of consensus panel 1 from the 11(th) International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naive patients.
Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D'Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J. Buske C, et al. Semin Hematol. 2023 Mar;60(2):73-79. doi: 10.1053/j.seminhematol.2023.03.005. Epub 2023 Mar 29. Semin Hematol. 2023. PMID: 37099027 Clinical Trial.
Consensus Panel 1 (CP1) of the 11(th) International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management of symptomatic, treatment-naive patients with WM. ...While the overall findings of a prospective, randomi …
Consensus Panel 1 (CP1) of the 11(th) International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with upda …
Waldenstrom macroglobulinemia.
Vijay A, Gertz MA. Vijay A, et al. Blood. 2007 Jun 15;109(12):5096-103. doi: 10.1182/blood-2006-11-055012. Epub 2007 Feb 15. Blood. 2007. PMID: 17303694 Free article. Review.
In the past 36 months, new developments have occurred both in the understanding of the biology of Waldenstrom macroglobulinemia (WM) and in therapeutic options for WM. ...The most common symptom is fatigue attributable to anemia. The prognostic factors predictive …
In the past 36 months, new developments have occurred both in the understanding of the biology of Waldenstrom macroglobulinemia …
Waldenstrom macroglobulinemia: prognosis and management.
Oza A, Rajkumar SV. Oza A, et al. Blood Cancer J. 2015 Mar 27;5(3):e394. doi: 10.1038/bcj.2015.28. Blood Cancer J. 2015. PMID: 25815903 Free PMC article. Review.
Waldenstrom macroglobulinemia (WM) is a B-cell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M protein in the serum and infiltration of bone marrow with lymphoplasmacytic cells. ...Initial therapy is usually administered for 6 months, followe …
Waldenstrom macroglobulinemia (WM) is a B-cell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M protein …
Waldenstrom macroglobulinemia: my way.
Gertz M. Gertz M. Leuk Lymphoma. 2013 Mar;54(3):464-71. doi: 10.3109/10428194.2012.717173. Epub 2012 Aug 25. Leuk Lymphoma. 2013. PMID: 22860921 Review.
Waldenstrom macroglobulinemia is a lymphoplasmacytic lymphoma. A serum monoclonal IgM protein is required to establish this diagnosis. ...Some patients with Waldenstrom macroglobulinemia have a smoldering form and can be observed without interve …
Waldenstrom macroglobulinemia is a lymphoplasmacytic lymphoma. A serum monoclonal IgM protein is required to establish this di …
316 results